Genomic Testing Cooperative

What Genomic Testing Cooperative does

Genomic Testing Cooperative (GTC) is a clinical reference laboratory founded in 2018 that provides comprehensive DNA and RNA next-generation sequencing (NGS) profiling for solid tumors and hematologic malignancies. Headquartered in Lake Forest, California, the company operates a cooperative business model in which hospitals, laboratories, and pathology groups can either internalize NGS testing under GTC's managed infrastructure or use GTC as a reference lab. Its test menu covers more than 300-400 DNA genes and more than 1,600 RNA genes, and includes the proprietary Liquid Trace® liquid biopsy that analyzes both cell-free DNA and cell-free RNA from peripheral blood or cerebrospinal fluid, alongside tissue-based Solid Tumor Profile Plus™, Hematology Profile Plus™, and complementary IHC testing.

GTC's technology stack rests on Illumina NovaSeq 6000 sequencing integrated with its proprietary Interprestation™ software, which applies AI and machine learning to automate interpretation of complex NGS data, predict therapy response, and—per company research—classify lymphomas as an alternative to immunohistochemistry and flow cytometry. All tests are Medicare-approved through Palmetto GBA/MolDx, including the first Palmetto-covered liquid biopsy for hematology. GTC generates revenue through clinical laboratory testing billed to Medicare and commercial payors, supplemented by professional services for pharmaceutical and research customers (biomarker discovery, companion diagnostics, digital molecular sample bank). Distribution is direct to enterprise healthcare providers in North America and through international representative offices in Glasgow (UK) and Heidelberg (Germany), with a European channel partnership via Labor Dr. Wisplinghoff.

The company is led by founder, CEO, and Chief Medical Officer Dr. Maher Albitar, with a headcount of 11-50. Recent strategic activity includes a 6,900-square-foot laboratory opening in The Woodlands/Houston, Texas (March 2026) positioned to access the Texas Medical Center ecosystem, an internalization partnership with Summit Health (part of VillageMD) in May 2025, and ongoing development of CSF-based liquid biopsy and ML-driven lymphoma classification tests.

Name

Genomic Testing Cooperative

Legal name

Genomic Testing Cooperative, LCA

Website

https://genomictestingcooperative.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Genomic Testing Cooperative (GTC) is a clinical reference laboratory that provides DNA and RNA NGS profiling for solid tumors and hematologic malignancies through a cooperative model, using AI-powered Interprestation™ software and Medicare-covered Liquid Trace® liquid biopsy tests.

Ownership category

akta.pro rank

Product category

Clinical Molecular Diagnostics

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

Keywords

• Clinical genomic profiling
• Next-generation sequencing
• Liquid biopsy testing
• Molecular diagnostics
• Cancer genomic testing

Headquarters

HQ city

Irvine

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Laboratory Testing Services: GTC provides comprehensive genomic profiling tests for solid tumors and hematologic malignancies. Revenue is generated through direct billing to Medicare and commercial health insurance plans. The company handles insurance claims processing and appeals directly on behalf of patients.
2. Pharma and Research Services: GTC offers services to pharmaceutical companies including research partnerships, digital molecular sample bank, biomarker data, gene expression analysis, and companion diagnostics development.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Genomic Testing Cooperative operates a clinical reference laboratory that provides comprehensive DNA and RNA next-generation sequencing profiling for cancer diagnostics, including solid tumors and hematologic malignancies. The portfolio spans liquid biopsy tests (Liquid Trace®) using cell-free DNA/RNA from blood or cerebrospinal fluid, tissue-based solid tumor profiles (DNA and RNA), hematology profiles, immunohistochemistry, and the proprietary Interprestation™ AI-powered interpretation software. Tests detect tumor mutation burden, microsatellite instability, homologous recombination deficiency, fusions, copy number variations, and gene expression, with results delivered in 5-10 days.

Product overview

Genomic Testing Cooperative (GTC) offers a portfolio of comprehensive genomic profiling tests for oncology diagnostics. The core offerings include liquid biopsy tests (Liquid Trace®) for non-invasive testing via blood or CSF, and tissue-based NGS testing for solid tumors and hematologic malignancies. Test menus span DNA sequencing (>300-400+ genes), RNA sequencing (>1600 genes), and combined DNA+RNA profiling panels. The portfolio includes Solid Tumor Profile Plus™ (DNA+RNA), Solid Tumor Profile™ (DNA-only), Solid Tumor Fusion/Expression Profile (RNA-only), Hematology Profile Plus™ (DNA+RNA), and Hematology Profile™ (DNA-only). These are complemented by Interprestation™ software for automated genomic interpretation. The tests cover tumor mutation burden (TMB), microsatellite instability (MSI), homologous recombination deficiency (HRD), gene fusions, copy number variations, and gene expression. GTC also offers IHC testing as a complementary service. Turnaround time is 5-7 days for DNA-only tests and 7-10 days for tests including RNA. The company operates a cooperative model allowing labs to internalize or outsource NGS testing.

Differentiator

Problem solved

Functional benefit

Brands

• Liquid Trace®: Non-invasive liquid biopsy test for solid tumors and hematologic malignancies using cell-free DNA (cfDNA) and cell-free RNA (cfRNA)
• Solid Tumor Profile Plus™
• Hematology Profile Plus™
• Interprestation™

Products and services

• Liquid Trace® Non-invasive liquid biopsy test using cell-free DNA (cfDNA) and cell-free RNA (cfRNA) from peripheral blood or cerebrospinal fluid to detect molecular abnormalities in solid tumors and hematologic malignancies, reducing the need for invasive tissue biopsies.
• Solid Tumor Profile Plus™ Comprehensive NGS testing for solid tumors covering >400 DNA genes and >1600 RNA genes, detecting tumor mutation burden (TMB), microsatellite instability (MSI), homologous recombination deficiency (HRD), fusions, copy number variations, and gene expression for all solid tumor types.
• Solid Tumor Profile™ NGS DNA testing for solid tumors detecting mutations in >400 genes, copy number variation, chromosomal structural abnormalities, TMB, MSI, and HRD across all solid tumor types.
• Solid Tumor Fusion/Expression Profile RNA sequencing for solid tumors detecting fusions (ALK, ROS1, RET, BRAF, NTRK1/2/3, FGFR1/2/3/4, CIC, EWSR1), gene expression (PD-L1, MYC, CCND1, MET, FGFR1/2/3/4, Ki67, ERBB2, MDM2), and alternative splicing including MET exon 14 skipping and EGFRvIII.
• Hematology Profile Plus™ Comprehensive hematologic molecular profiling covering >300 DNA genes and >1600 RNA/cfRNA genes for all hematologic neoplasms including lymphoma, multiple myeloma, acute lymphoblastic leukemia, acute myeloid leukemia, MDS, CMML, MPN, and VEXAS syndrome.
• Hematology Profile™ NGS DNA testing for hematologic diseases covering >300 genes, used for diagnosis of MDS, CMML, AML, MPN (JAK2, CALR, MPL), minimal residual disease (MRD), and multiple myeloma.
• Interprestation™ Advanced genomic analysis software that automates interpretation of complex NGS data, providing rapid assessment of genomic alterations and their clinical impact on prognosis, diagnosis, and therapy response prediction using AI/ML algorithms.
• IHC Testing Immunohistochemistry testing service for solid tumors, offered as a complementary test to NGS profiling.

Quantifiable outcome

• Less than 0.5% QNS (Quality Not Sufficient) rate for 2023-2024 results
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• Summit Health (VillageMD)coreStrategic or Co-development Partner · 20 May 2025Summit Health, part of VillageMD, has internalized Genomic Testing Cooperative's next-generation sequencing DNA and RNA profiling tests at its Woodland Park, NJ laboratory. This partnership covers solid tumors and hematologic neoplasms including GTC's peripheral blood-based liquid biopsy assay, Liquid Trace. By bringing testing in-house, Summit Health expects to reduce send-out burdens to multiple labs, standardize data collection, shorten turnaround times, and gain access to GTC's Co-Op network for R&D, clinical trials, and IP development.
• Labor Dr. WisplinghoffcoreChannel Partner/ Reseller/ DistributorLabor Dr. Wisplinghoff partnered with GTC to deploy GTC's comprehensive suite of tissue and liquid biopsy testing in Germany. This partnership covers solid tumor and hematologic neoplasms testing, expanding GTC's presence in the European market.
• IlluminacoreTechnology or IntegrationGTC uses Illumina NovaSeq 6000 sequencing technology in their laboratory for next-generation sequencing operations.

Scale indicators6 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Foundation Medicine: Direct competitor offering comprehensive genomic profiling (DNA and RNA) for solid tumors and hematologic malignancies. Most direct overlap on NGS-based comprehensive profiling and pharma/biopharma companion diagnostics partnerships, though Foundation Medicine operates at substantially larger scale (Roche subsidiary).
• Tempus Labs: Direct competitor in NGS-based oncology profiling, AI-driven clinical reporting, and pharma/biopharma data services. Overlaps with GTC on comprehensive tumor profiling, AI interpretation, and pharma partnering offerings, but operates at vastly larger scale with broader test menu.
• Caris Life Sciences: Direct competitor offering DNA and RNA molecular profiling (MI Profile), liquid biopsy (Caris Assure), and AI-powered analytics for oncology. Closely comparable comprehensive DNA+RNA profiling model and pharma/biopharma services focus.
• Guardant Health: Direct competitor in liquid biopsy oncology testing (Guardant360) and comprehensive genomic profiling. Particularly comparable on the Liquid Trace® liquid biopsy offering, though Guardant operates at substantially larger commercial scale and broader payer coverage.
• NeoGenomics: Direct competitor as a specialty oncology reference laboratory offering comprehensive genomic profiling, hematology testing, and pharma services. Comparable business model as a clinical reference lab serving oncologists and pathologists with similar test menu overlap.
• Personalis: Direct competitor in NGS-based oncology profiling with a focus on combined DNA+RNA whole-genome analysis (NeXT Personal). Closely comparable technology approach combining DNA and RNA sequencing for comprehensive tumor characterization.
• Natera: Comparable in oncology liquid biopsy and minimal residual disease (MRD) testing. Overlaps with GTC's Liquid Trace® offering for hematologic and solid tumor monitoring, though Natera is more focused on MRD recurrence monitoring.

Broad incumbents

• PathGroup: Broader anatomic and molecular pathology reference laboratory offering oncology testing including NGS. Overlaps on the clinical reference lab business model serving community oncologists, though PathGroup is a broader diagnostics provider rather than a pure-play NGS oncology specialist.

Regional players

• Burning Rock Biotech: Comparable NGS-based oncology profiling company (China-focused) offering comprehensive DNA+RNA panels and pharma services. Similar technology approach but primarily serves the Chinese market, providing an international reference point for GTC's positioning.

Others

• Illumina: Technology infrastructure partner to GTC (NovaSeq 6000 platform) and broader NGS ecosystem enabler. Comparable in the sense that Illumina's sequencing platforms underpin the entire NGS clinical lab industry, including GTC's operations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/GenomicTesting
• YouTubeyoutube.com/channel/UCL8wmL0l2_CS07geapSrDSg
• Facebookfacebook.com/GenomicTesting
• LinkedInlinkedin.com/company/genomic-testing-cooperative

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genomic Testing Cooperative